Navigation Links
Kuvan Receives Priority Review Status From Health Canada
Date:6/10/2009

is in clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase 1/2 clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the continued development and commercialization of Kuvan and BioMarin's other products and product candidates and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the continued commercialization of Kuvan; the content and timing of decisions by the U.S. Food and Drug Administration, Health Canada and other regulatory authorities concerning each of the described products and product candidates; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2008 Annual Report on Form 10-K, as amended, and the factors contained in BioMarin's reports on Form 10-Q and Form 8-K. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R), Naglazyme(R) and Kuvan(R) are a registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan
2. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
3. Kuvan Receives Positive Opinion From CHMP for European Approval
4. Kuvan Receives Marketing Approval in the European Union
5. BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
6. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
7. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
10. IsoTis Receives FDA Clearance for Accell Family of Products
11. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 27, 2015 Research and Markets( ... Jain PharmaBiotech,s new report "Nanobiotechnology Applications, ... An increasing use of nanobiotechnology ... anticipated. Nanotechnology will be applied at all ... for optimal delivery to diagnostic applications in ...
(Date:5/28/2015)... -- Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... institutional healthcare investors to purchase an aggregate of approximately ... at-the-market registered direct offering and a concurrent private placement ... Company entered into a definitive purchase agreement with these ... an aggregate of 3,000,000 shares of its common stock ...
(Date:5/28/2015)... RXi Pharmaceuticals Corporation (NASDAQ: RXII ), ... therapeutics, primarily in the areas of dermatology and ophthalmology, ... 26 million units at a price to the public ... $10.4 million. Each unit consists of (i) one share ... to purchase 0.50 of a share of common stock ...
(Date:5/28/2015)... Glenn Keet, CEO of Clinovo , ... Clinical Data Integration with EDC Systems ” at the ... on June 14th-18th. , During the presentation, Glenn Keet ... EDC, and will examine the value of patient engagement, ... health records/electronic medical records integration. , The presentation ...
Breaking Biology Technology:Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 3Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3Clinovo Presents at the DIA 2015 51st Annual Meeting in Washington, DC on June 14th-18th 2
... Aug. 16, 2011 Quanterix Corporation, a company ... based on its revolutionary Si ngle ... STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX), ... of automated analyzer systems, today announced an agreement ...
... The Society of Interventional Radiology Foundation launched a ... the future of the specialty with its announcement ... student conducting preclinical research in interventional radiology during ... prestigious Medical Research Fellows Program. (Logo: ...
... 2011 PharmAthene, Inc. (NYSE Amex: PIP ... and chemical threats, announced today that the Company has ... of Defense (DoD) Broad Agency Announcement for studies directed ... the bioproduction of its nerve agent medical countermeasure program. ...
Cached Biology Technology:Quanterix and STRATEC Announce Strategic Partnership 2Quanterix and STRATEC Announce Strategic Partnership 3Society of Interventional Radiology Foundation Funds Howard Hughes Medical Institute Award 2Society of Interventional Radiology Foundation Funds Howard Hughes Medical Institute Award 3Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program 2Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program 3Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program 4
(Date:5/11/2015)... 11, 2015  Through a well-rounded UAS delegation representing private ... a strong showing at AUVSI,s Unmanned 2015 conference last week ... Ohio,s UAS industry met with over 200 ... points along the UAS ecosystem. "Our message ... President for Aerospace Rich Knoll . "If you want ...
(Date:5/10/2015)... 2015 Fingerprint Cards (FPC) has received ... from the distributor World Peace Industrial Group (WPI), part of ... Asia . Deliveries are planned to take place ... smartphone manufacturers in China . The order ... guidance of + 1 000 MSEK for 2015.   ...
(Date:5/7/2015)... 2015 Fingerprint Cards (FPC) ... FPC1035, FPC,s smallest touch fingerprint sensors to date.  ... for integration on the backside of the phone, ... possibilities to integrate touch fingerprint sensors in the ... possibilities for module manufacturers to customize the look ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... of Nature Chemistry , ASU scientists, along with ... perfecting a functional artificial leaf. Designing an artificial ... and efficiently into hydrogen and oxygen is one of ... Center, funded by the Department of Energy, in the ...
... that packs twice the energy compared to current microbatteries used ... Pacific Northwest and around the world. The battery, a ... is certainly not the world,s smallest battery, as engineers have ... hair. But those smaller batteries don,t hold enough energy to ...
... Led by biomedical engineer Justin Zook of the National ... from Harvard University and the Virginia Bioinformatics Institute ... methods to integrate data from different sequencing platforms, thus ... genome sequencing. "Understanding the human genome is an ...
Cached Biology News:Artificial leaf jumps developmental hurdle 2A battery small enough to be injected, energetic enough to track salmon 2A battery small enough to be injected, energetic enough to track salmon 3A battery small enough to be injected, energetic enough to track salmon 4Research team establishes benchmark set of human genotypes for sequencing 2
...
... Materials for 15-20 enhancements when used as directed, ... Enhancement System is designed to amplify the desired signal ... for evaluating proteins with low expression., ... to blocking the membrane; 1x solution; 250 ml, ...
Applications: Western blotting ...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Biology Products: